重组人生长激素对特发性矮小症患儿身高及血清胰岛素样生长因子1的影响  

Effect of recombinant human growth hormone on height and serum IGF-1 in children with idiopathic short stature

作　　者：杨志敏 鞠海超 Yang Zhimin;Ju Haichao(Department of Pediatrics,Weihai Central Hospital,Weihai,Shandong 264400,China)

机构地区：[1]威海市中心医院儿科,山东省264400

出　　处：《中国基层医药》2020年第19期2334-2338,共5页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的:研究重组人生长激素对特发性矮小症患儿身高和血清胰岛素样生长因子1水平(IGF-1)的影响。方法:选取2015年9月至2017年2月威海市中心医院儿科收治的特发性矮小症患儿50例,采用随机数字表法分为治疗组(25例)和对照组(25例)。对照组患者采用营养支持治疗,治疗组在对照组治疗的基础上加用重组人生长激素皮下注射治疗,所有患儿治疗并观察1年。统计患儿治疗前后身高、体质量、生长速率、骨龄、总甲状腺激素水平、空腹血糖水平、IGF-1和不良反应情况。结果:治疗1年后,两组患儿身高、生长速率、IGF-1均较治疗前显著提高(t=4.427、2.987、7.459、5.963、31.389、21.790,P<0.001、0.004、<0.001、<0.001、<0.001、<0.001),且治疗组显著高于对照组(t=2.914、2.480、12.090,P=0.006、0.017、<0.001)。两组患儿体质量、骨龄、总甲状腺激素水平、空腹血糖水平与治疗前相比未见明显改变(t=0.548、1.931、0.300、1.367、0.735、0.759、0.693、0.920,P=0.586、0.060、0.765、0.179、0.466、0.452、0.492、0.362),且治疗组与对照组相比无明显变化(t=0.371、0.141、0.059、0.318,P=0.713、0.889、0.953、0.752)。治疗过程中两组患儿不良反应发生率差异无统计学意义(χ2=2.083,P=0.149)。结论:重组人生长因子能有效加快特发性矮小症患儿的生长速度,增加患儿身高、提高血清IGF-1水平,且无明显不良反应。Objective:To study the effect of recombinant human growth hormone on height and serum insulin-like growth factor 1(IGF-1)in children with idiopathic short stature.Methods:Fifty children with idiopathic short stature admitted to Weihai Central Hospital from September 2015 to February 2017 were randomly divided into treatment group(25 cases)and control group(25 cases)according to the random digital table method.The control group received nutritional support treatment.The treatment group was treated with subcutaneous injection of recombinant human growth hormone on the basis of the control group.All the children were treated and observed for one year.The height,weight,growth rate,bone age,total thyroid hormone level,fasting blood glucose level,serum IGF-1 level and adverse reactions were compared before and after treatment.Results:After 1 year of treatment,the height,growth rate,and IGF-1 of the two groups were significantly higher than those before treatment(t=4.427,2.987,7.459,5.963,31.389,21.790,P<0.001,0.004,<0.001,<0.001,<0.001,<0.001).which in the treatment group were significantly higher than those in the control group(t=2.914,2.480,12.090,P=0.006,0.017,<0.001).The body weight,bone age,total thyroid hormone levels,and fasting blood glucose levels in the two groups were not significantly different from those before treatment(t=0.548,1.931,0.300,1.367,0.735,0.759,0.693,0.920,P=0.586,0.060,0.765,0.179,0.466,0.452,0.492,0.362),and there were no statistically significant differences between the two groups(t=0.371,0.141,0.059,0.318,P=0.713,0.889,0.953,0.752).There was no statistically significant difference in adverse reactions between the two groups during treatment(χ2=2.083,P=0.149).Conclusion:Recombinant human growth factor can effectively accelerate the growth rate of children with idiopathic short stature,increase the height of children,increase the level of serum IGF-1,and has no obvious side effects.

关 键 词：身高 胰岛素样生长因子结合蛋白质1 生长激素 甲状腺素 血糖 儿童 

分 类 号：R725.8[医药卫生—儿科]